RxDoctor Payments Data

Andrew Lavey, OD

Optometrist · Sheboygan, WINPI 1710953609

Payments from drug & device makers

$1,755in general payments, 2019–2025

Across 37 payments — averaging $47.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$142
  • Oyster Point Pharma, Inc.$97
  • Regeneron Healthcare Solutions, Inc.$92
  • Sun Pharmaceutical Industries Inc.$48
  • Tarsus Pharmaceuticals, Inc.$39
  • plus $151 from 8 others

What the payments were for

  • Travel & lodging$80146%
  • Food & beverage$93653%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,755 in reported general payments places this provider in the 80th percentile of 867 optometrist providers in Wisconsin.

See all optometrist providers in Wisconsin

Medicare billing

Part B allowed, 2024
$97,873
Medicare patients
610
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine89$63,615
XiidraLifitegrast32$32,781
LumiganBimatoprost27$18,815
Cyclosporine25$16,041
TyrvayaVarenicline Tartrate16$9,491
Latanoprost659$7,275
Brimonidine Tartrate100$5,118
Travoprost32$4,628
Prednisolone Acetate54$3,155
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$2,142
Ketorolac Tromethamine31$1,865
Timolol Maleate191$1,788
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat96$1,745
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha88$1,107
ErythromycinErythromycin Base57$803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$142$82,430116 claims
Bausch & Lomb Americas Inc.Xiidra$33$32,78132 claims
Oyster Point Pharma, Inc.Tyrvaya$97$9,49116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 867 optometrist providers in Wisconsin.

Other optometrist in Sheboygan

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →